Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2019 pubmed 26 citations

Salivary antimicrobial proteins and stress biomarkers are elevated during a 6-month mission to the International Space Station.

Agha. Nadia H NH; Baker. Forrest L FL; Kunz. Hawley E HE; Spielmann. Guillaume G; Mylabathula. Preteesh L PL; Rooney. Bridgette V BV; Mehta. Satish K SK; Pierson. Duane L DL; Laughlin. Mitzi S MS; Markofski. Melissa M MM; Crucian. Brian E BE; Simpson. Richard J RJ

Key Findings

  • Salivary LL‑37, lysozyme, and secretory IgA were elevated before launch and during the mission.
  • Rookie astronauts showed larger increases in LL‑37 than veterans.
  • Crew members who re‑activated latent herpes viruses had higher cortisol (stress) levels.

Practical Outcomes

  • For biohackers, LL‑37 appears to be a stress‑responsive immune marker rather than a direct supplement target. Monitoring stress hormones and supporting overall stress reduction (sleep, nutrition, relaxation) may help keep immune function stable during extreme conditions. LL‑37 itself isn’t currently a practical intervention, but its rise signals that stress management is crucial for maintaining immunity.

Summary

During a six‑month stay on the International Space Station, astronauts showed higher levels of the natural antimicrobial peptide LL‑37 (along with other immune proteins) in their saliva, especially before launch and early in the mission. First‑time flyers had the biggest spikes, and those who re‑activated latent viruses also had higher stress hormones.

Abstract

As the international space community plans for manned missions to Mars, spaceflight-associated immune dysregulation has been identified as a potential risk to the health and safety of the flight crew. There is a need to determine whether salivary antimicrobial proteins, which act as a first line of innate immune defense against multiple pathogens, are altered in response to long-duration (&gt;6 mo) missions. We collected 7 consecutive days of whole and sublingual saliva samples from eight International Space Station (ISS) crewmembers and seven ground-based control subjects at nine mission time points, ~180 and ~60 days before launch (L-180/L-60), on orbit at flight days ~10 and ~90 (FD10/FD90) and ~1 day before return (R-1), and at R+0, R+18, R+33, and R+66 days after returning to Earth. We found that salivary secretory (s)IgA, lysozyme, LL-37, and the cortisol-to-dehydroepiandrosterone ratio were elevated in the ISS crew before (L-180) and during (FD10/FD90) the mission. "Rookie" crewmembers embarking on their first spaceflight mission had lower levels of salivary sIgA but increased levels of &#x3b1;-amylase, lysozyme, and LL-37 during and after the mission compared with the "veteran" crew who had previously flown. Latent herpesvirus reactivation was distinct to the ~6-mo mission crewmembers who performed extravehicular activity ("spacewalks"). Crewmembers who shed at least one latent virus had higher cortisol levels than those who did not shed. We conclude that long-duration spaceflight alters the concentration and/or secretion of several antimicrobial proteins in saliva, some of which are related to crewmember flight experience, biomarkers of stress, and latent viral reactivation.<b>NEW &amp; NOTEWORTHY</b> Spaceflight-associated immune dysregulation may jeopardize future exploration-class missions. Salivary antimicrobial proteins act as a first line of innate immune defense. We report here that several of these proteins are elevated in astronauts during an International Space Station mission, particularly in those embarking on their first space voyage. Astronauts who shed a latent herpesvirus also had higher concentrations of salivary cortisol compared with those who did not shed. Stress-relieving countermeasures are needed to preserve immunity and prevent viral reactivation during prolonged voyages into deep space.

Study Information

Provider

pubmed

Year

2019

Date

2019-11-21T00:00:00.000Z

DOI

10.1152/japplphysiol.00560.2019

Citations

26

References

57